Most Recent
‘Heed this caution’: Judge warns parties risk costs for filing irrelevant docs
A judge has hit a container systems company with indemnity costs for tendering hundreds of pages of irrelevant evidence in a trade mark dispute and warned "future litigants that fail to heed this caution" face costs risks.
AstraZeneca can inspect Pharmacor emails in fight over Forxiga patent
AstraZeneca can inspect Pharmacor's emails to verify its claim that the merits of its challenge to a patent extension for blockbuster diabetes drug Forxiga were not appreciated at an earlier time, with a judge finding Pharmacor had waived privilege. 
AstraZeneca probes Pharmacor’s delayed defence in Forxiga patent fight
Pharmacor is resisting AstraZeneca’s notice to produce in an intellectual property fight over diabetes drug Forxiga, claiming privilege over material evidencing its consideration of a new claim challenging the validity of a patent extension.
High Court to hear Otsuka challenge to Abilify patent extension ruling
The High Court has agreed to hear Otsuka's appeal of a decision that revoked its Abilify patent extension, which Otsuka argued would “lead to a groundswell of court proceedings”.
Pharmacor targets patent extension in fight over AstraZeneca’s Forxiga
Pharmacor wants to amend its defence in AstraZeneca's suit over the Australian drug maker's plans to launch a generic version of diabetes drug Forxiga so that it can argue a patent extension for the drug should not have been granted.
AstraZeneca wins injunction against Pharmacor’s generic diabetes drug
AstraZeneca has won an interlocutory injunction barring Pharmacor from making a generic version of its blockbuster diabetes drug Forxiga while a patent case over the drug proceeds.
‘Not responsible litigants’: Fed-up judge issues 30th judgment in vodka TM case
After years of pre-trial stoushes, a trademark dispute over Russian vodka has worn a Federal Court judge's patience thin, with the judge remarking that the court was entitled to expect better from the litigants.
Sun Pharma defeats appeal over Otsuka’s injectable Abilify patent
The Full Federal Court has upheld a decision revoking Otsuka Pharmaceuticals’ patent extension for an injectable version of antipsychotic drug Abilify, finding the patent expired last year.
Regeneron, Bayer settle appeal over launch of Sandoz’s Eylea biosimilar
Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea. 
Fortescue, Element Zero reach settlement in trade secrets case
After losing a fight over access to millions of seized documents, Fortescue has settled its trade secrets case against green iron company Element Zero.